AdvaMed Accel Member Webinar: Paycheck Protection Program

AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker upon the passage of a research and development expensing tax provision critical to medtech innovation in the House of Representatives.

Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today urged Congress to enact a research and development expensing tax provision critical to medtech innovation. The provision would delay a change requiring businesses to deduct their research and development expenses over five years, allowing immediate deduction.

Learn how to develop and maintain an effective and innovative business model to stand out and find success in the medtech industry.

 The United States International Trade Commission (USITC) released its highly anticipated report,“COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TRIPS Agreement Flexibilities” on October 17. Evidence presented in the 496-page report supports AdvaMed’s position that there is no justification for the World Trade Organization (WTO) to waive intellectual property protection for products used to treat or diagnose COVID-19.

Join us for a breakdown of the Chinese medical device market, to review the current regulatory requirements and pathways, and address I.P. protection in China for U.S. companies.

Following the introduction of the bipartisan American Innovation and Jobs Act in the U.S. Senate and its House companion the American Innovation and R&D Competitiveness Act, AdvaMed, the MedTech Association, called on lawmakers to quickly pass the legislation which would allow for small companies to deduct their research and development expenses in the year they are incurred. Currently, companies are required to deduct their expenses over the course of five years.

AdvaMed’s medtech priorities for the 118th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.